We are live on
!
Find out more
Sands Capital Management Portfolio holdings
AUM
$25.5B
1-Year Est. Return
26.46%
This Fund
S&P 500
This Quarter
Est. Return
+14.31%
1 Year Est. Return
+26.46%
3 Year Est. Return
+130.81%
5 Year Est. Return
+100.92%
10 Year Est. Return
+877.17%
AUM
$34.4B
AUM Growth
+$3.33B
(+11%)
Cap. Flow
-$523M
Cap. Flow
% of AUM
-1.52%
Top 10 Holdings %
Top 10 Hldgs %
47.08%
Holding
79
New
1
Increased
37
Reduced
36
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$309M |
| 2 |
Sea Limited
SE
|
+$307M |
| 3 |
Zoetis
ZTS
|
+$224M |
| 4 |
Match Group
MTCH
|
+$195M |
| 5 |
Microsoft
MSFT
|
+$184M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$375M |
| 2 |
Edwards Lifesciences
EW
|
+$312M |
| 3 |
Incyte
INCY
|
+$308M |
| 4 |
Palo Alto Networks
PANW
|
+$265M |
| 5 |
Netflix
NFLX
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.7% |
| 2 | Consumer Discretionary | 20.36% |
| 3 | Healthcare | 19.63% |
| 4 | Communication Services | 15.89% |
| 5 | Financials | 9.8% |
Similar funds
KK
VAI
UIM
SO
Sands Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Sands Capital Management held 79 positions worth $34.4B, up 11% from $31.1B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Sands Capital Management's Q4 2019 filing shows 1 new, 37 increased, 36 reduced and 4 closed positions. Its largest new stake was iShares Russell 1000 Growth ETF: 136,140 shares worth $5.99M. The largest sale was BioMarin Pharmaceuticals, an estimated $375M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Sands Capital Management's largest Q4 2019 buy was iShares Russell 1000 Growth ETF: 136,140 shares worth $5.99M.
- Sands Capital Management added most to Intuit in Q4 2019, an estimated $309M increase.
- Sands Capital Management's biggest Q4 2019 reduction was Edwards Lifesciences, cutting an estimated $312M.
- Sands Capital Management fully exited BioMarin Pharmaceuticals in Q4 2019, selling an estimated $375M.
- Sands Capital Management's ten largest holdings make up 47% of its $34.4B portfolio in Q4 2019.
- Sands Capital Management opened 1 new position and closed 4 in Q4 2019.
- Sands Capital Management's portfolio value rose 11% quarter-over-quarter to $34.4B.
Based on Sands Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.